General Information of Drug (ID: DM54A3W)

Drug Name
4-methoxy-9-aminomethyl-9,10-dihydroanthracene Drug Info
Synonyms CHEMBL454491; 4-methoxy-9-aminomethyl-9,10-dihydroanthracene; BDBM50264950
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44580318
TTD Drug ID
DM54A3W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 2A receptor (HTR2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [2]
ZOTEPINE DMF3VXA Anxiety disorder 6B00-6B0Z Approved [3]
Iloperidone DM6AUFY Schizophrenia 6A20 Approved [4]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [5]
Lurasidone hydrochloride DMCVPXO Schizophrenia 6A20 Approved [6]
Aniracetam DMOIFW0 Cerebrovascular ischaemia 8B1Z Approved [7]
lumateperone tosylate DMQ8HOJ Schizophrenia 6A20 Approved [8]
Sarpogrelate DMGLP6S Diabetic complication 5A2Y Approved [9]
Pimavanserin DMR7IVC Parkinson disease 8A00.0 Approved [10]
Zicronapine DMP8ESD Schizophrenia 6A20 Phase 3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Inhibitor [1]

References

1 Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71.
2 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
3 Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
4 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
10 Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
11 Clinical pipeline report, company report or official report of Lundbeck.